Reported side effects following COVID-19 vaccination in Canada
Select “Weekly Report”

There have been a total of 2,530 reports . . . up to and including March 19, 2021. Of the 2,530 reports, 320 were considered serious . . . .

Total doses administered: 3,729,312

Figure 4 (Text Description)
Most frequently reported adverse events up to and including March 19, 2021 (n=7,397)
Most frequently reported adverse events Number of adverse events
Vaccination site pain 656
Vaccination site erythema (redness) 524
Vaccination site swelling 392
Pruritus (itching) 329
Vaccination site warmth 323
Vaccination site reaction 307
Paraesthesia (tingling or prickling) 301
Headache 275
Urticaria (hives) 239
Nausea 215
Adenopathy/lymphadenopathy (swollen lymph nodes) 213
Rash 211
Vaccination site pruritus (itching) 207
Fever ≥ 38°C 195
Fatigue 192
Vaccination site cellulitis 173
Dizziness 171
Dyspnoea (laboured breathing) 158
Erythema (redness) 153
Hypoaesthesia (numbness) 152
Chills 143
Vaccination site inflammation 136
Vomiting 123
Pain 122
Other allergic reactions 121
Vaccination site induration (hardness) 118
Vaccination site rash 106
Throat tightness 103
Diarrhea 102
Tachycardia (fast heartbeat) 96
Chest discomfort 91
Arthralgia (joint pain) 86
Myalgia (muscle pain) 79
Dermatitis allergic 75
Extensive swelling of vaccinated limb 71
Flushing 66
Dysphagia (difficulty swallowing) 66
Malaise (discomfort) 66
Swelling face 62
Lip swelling 61
Cough 59
Anaphylaxis 59

Deaths is separated:

Up to and including March 19, 2021, a total of 24 reports identified deaths that occurred after the administration of a vaccine. Following medical case review, it has been determined that 13 of these deaths are not linked to a COVID-19 vaccine and the other 11 are still under investigation. When the investigation is complete, the number will be updated accordingly.

The current reports do not suggest any unusual characteristics of adverse events following administration of COVID-19 vaccines in Canada. Safety concerns have not been identified in Canada’s adverse event reports at this time. There have been reports in Europe of blood clots associated with low levels of blood platelets (thrombocytopenia) following vaccination with the AstraZeneca COVID-19 vaccine. Health Canada is aware of the situation and will continue to monitor these developments closely.

“Data Notes” at the bottom indicate the nature of this data:
For example, point #2:

Information is collected on individuals for whom an report was submitted, not on the total number of individuals who experience an adverse event as not every adverse event is reported.

Vaccination coverage:
I have selected a few figures:
“9.18% of the population has received at least one dose”
“59.69% of adults aged 80 or older have received at least one dose”
“91.05% of adults in group living settings for seniors have received at least one dose”

“75.38% of health care workers targeted for priority vaccination have received at least one dose”

Adverse event following immunization reports by vaccine name

Figure 2 shows the breakdown of reports by vaccine name. . . . COVID-19 vaccines approved for use in Canada currently include: Pfizer-BioNTech, Moderna, AstraZeneca, COVISHIELD (a version of the AstraZeneca vaccine manufactured by Verity Pharmaceuticals and the Serum Institute of India) and Janssen (Johnson and Johnson). While AstraZeneca and Janssen vaccines have been approved for use in Canada, they have not yet been distributed.

Vaccine name Non-serious reports Serious reports Total reports
Pfizer-BioNTech 1,181 263 1,444
Moderna 1,025 54 1,079
COVISHIELD 4 1 5

Related posts:
COVID-19 vaccine reports from VAERS (U.S. adverse event reporting system)
Summary of official adverse events reports at “COVID-19 vaccine safety in Canada”